ArticleTranslational andrology and urology2021
Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer.
Article in Translational andrology and urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- Noninvasive Urine Test Predicts Grade Group Upgrading in Patients on Active Surveillance for Prostate Cancer: Multisite Validation and Comparison with MRI.The Journal of urology · 2026Article
- Analytical Validation of MyProstateScore 2.0-Active Surveillance: A Urinary-Based Clinical RT-PCR Prostate Cancer Assay.Diagnostics (Basel, Switzerland) · 2026Article
- Key Determinants Influencing Treatment Decision-Making for and Adherence to Active Surveillance for Prostate Cancer: A Systematic Review.Journal of personalized medicine · 2025Review
- Assessment of Patient Experience During Active Surveillance for Prostate Cancer.Journal of patient experience · 2025Article
- Medication Adherence in Adults with Chronic Diseases in Primary Healthcare: A Quality Improvement Project.Nursing reports (Pavia, Italy) · 2024Article
- Patient perspectives on factors influencing active surveillance adherence for low-risk prostate cancer: A qualitative study.Cancer medicine · 2024Article
- Article
- Risk of progression following a negative biopsy in prostate cancer active surveillance.Prostate cancer and prostatic diseases · 2023Article
- When can cancer patient treatment nonadherence be considered intentional or unintentional? A scoping review.PloS one · 2023Article
- Developing a consensus statement for psychosocial support in active surveillance for prostate cancer.BJUI compass · 2023Article
- Selecting interventions for a psychosocial support program for prostate cancer patients undergoing active surveillance: A modified Delphi study.Psycho-oncology · 2022Review
- Exploring Variation in the Receipt of Recommended Active Surveillance for Men with Favorable-Risk Prostate Cancer.The Journal of urology · 2022Article
- Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database.The Prostate · 2022Article
- Expectant management in genitourinary malignancies (prostate, bladder, kidney).Translational andrology and urology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundActive surveillance (AS) is recommended by most national medical organizations as the preferred treatment option for men with low-risk prostate cancer (PCa). However, studies report that up to one third of men on AS dropout within 5 years, without evidence of disease progression. Despite high dropout rates, few studies have purposively explored the opinions and experiences of men who discontinued AS. The aim of this study was to gain insight into the reasons why some men on AS for PCa discontinue active treatment without evidence of disease progression.
methodsSemi-structured interviews were undertaken with 14 men from diverse socio-cultural backgrounds who had been on AS for PCa but dropped out of surveillance to undergo active treatment without signs of disease progression. Purposive sampling to reach data saturation was used to select participants based on their experience of AS and willingness to share their experiences. Interviews were transcribed and analysis undertaken in an inductive thematic manner.
resultsThe following themes arose from interviews as factors that potentially influence adherence to AS: men's experience at diagnosis and follow-up consultations, involvement in shared decision-making, the extent of supportive care and information, administrative procedures and support from partner and peers. A poor experience during diagnosis could adversely influence long-term adherence to AS, given the same diagnostic tests are frequently repeated. The provision of consistent information and support while on AS, similar to that offered to men undergoing radical treatment, was also highlighted as being important to increase confidence in the process.
conclusionsEffective communications skills among health professionals, aimed at building trust in patient-clinician relationships, providing opportunities for shared decision-making and developing self-efficacy, along with structured information and support, are key to enhancing long-term adherence to AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.